There’s a reason that venture firms in Boston love building their own companies: It helps to have a hand-picked leader with a proven track record at the helm of an early-stage biotech company.

Waltham, Mass.-based Skyhawk Therapeutics is bucking that trend with gusto. In June 2018, the company announced a $100 million early-stage venture fundraising round and partnership deals with Biogen and Celgene (which was just acquired by Bristol-Myers Squibb for $74 billion). Earlier this month, the company was at the annual J.P. Morgan Healthcare Conference looking for more. Yet their chief executive officer, Bill Haney, has less than five years of experience as a biotech executive; his only other biotech company is Dragonfly Therapeutics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Well, it seems like you will never be as good at convincing investors of anything, but rather sound like a complete tool who thinks he is owed something. And as to your credentials, you can shove them. Credentials don’t equal creativity… tool.

  • Fun fact:
    neither the CEO/co-founder, nor the CSO/co-founder have either an MD and/or a PhD degree. They must be so good they didn’t need one. Even more so, by claiming they are creating innovative treatments.

    I wish I was as good as them at convincing investors despite not having adequate scientific credentials. Maybe, that’s the problem, I actually have proper scientific credentials.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy